228 results about "Viral load" patented technology

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention relates to the technical field of agricultural biology, and particularly provides a dsRNA nanocrystallization preparation for preventing and treating areca yellows as well as a preparation method and application of the dsRNA nanocrystallization preparation. Areca yellows are a destructive disease caused by areca symptomless virus type 1 (APV1), eight key target gene segments of an APV1 virus genome are screened, specific double-stranded RNA is designed, a nano-carrier is used for wrapping and delivering a dsRNA mixture obtained by transcription of the eight target gene segments, and the areca yellows are obtained by screening. And a nanocrystallization preparation for improving the environmental stability and RNA interference efficiency of the dsRNA is prepared. Experimental results show that the nanocrystallization preparation can effectively inhibit the key gene expression of APV1 virus, reduce the virus load and improve the resistance of areca catechu to yellows. The invention provides an accurate, efficient and environment-friendly biological prevention and control strategy, and has a wide agricultural application prospect.

The invention discloses an alternative virus infection model capable of being used for simulating human Marburg virus disease symptoms under BSL-2 as well as an establishment method and application of the alternative virus infection model, and belongs to the technical field of biology. According to the invention, firstly, a recombinant vesicular stomatitis virus (VSV-MARV / GP) for expressing Marburg virus glycoprotein is constructed, and the VSV-MARV / GP is used as an alternative virus to cause lethal infection of a narrative hamster. The pathogenicity of the VSV-MARV / GP has species specificity, age correlation, gender correlation and attack pathway dependency. After infection of VSV-MARV / GP, female narrative hamsters of 5 weeks old show weight loss, multiple organ failure, high virus load and other symptoms and develop into serious systemic diseases similar to those observed by human MARV patients, and all animals die within two to three days after infection. The model provided by the invention can be used as an effective tool for carrying out rapid preclinical evaluation on medical countermeasures of MARV under the BSL-2 condition.

The invention discloses application of naringenin in preparation of a medicine for preventing and treating diseases caused by pseudorabies virus, and belongs to the technical field of biological medicine. The naringenin has good anti-PRV activity in vivo and in vitro. The naringenin can inhibit virus proliferation of the pseudorabies virus in an intracellular replication stage, reduce expression of PRV gB protein, lower expression of TLR4 and P65 protein to inhibit activation of an NF-kB pathway and lower expression of an inflammatory gene, and reduce nucleation of the NF-kB / P65 protein to achieve anti-inflammatory and antiviral effects. In-vivo experiments prove that naringenin can delay the disease time of mice, reduce the virus load in organs of the mice infected by PRV and relieve pathological changes of tissues and organs of the mice, and in addition, the survival rate of the mice infected by viruses is improved by adjusting the serum cell factor level of the mice. The naringenin provides a new strategy for preventing and treating PRV infection.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention discloses a veterinary vaccine composite adjuvant as well as a preparation method and application thereof. Active ingredients in the vaccine composite adjuvant are a manganese-containing compound and a Mincle agonist. According to the veterinary vaccine composite adjuvant disclosed by the invention, Mn and TDB are combined, so that the immunological enhancement effect of the TDB adjuvant is achieved. The composite adjuvant can induce a strong immune response reaction, significantly improves the immune effect, and is free of residual damage in use. Compared with the H7N9 vaccine prepared by singly using DDA-TDB, the H7N9 vaccine prepared by mixing the H7N9 subtype avian influenza inactivated virus as the antigen with the composite adjuvant can enhance humoral immunity and cellular immune response of a body, reduce virus load and improve protection level, and provides a product and technical support for production of veterinary vaccines.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention belongs to the technical field of biology, and particularly relates to a 3D protein mutated O-type foot-and-mouth disease recombinant virus strain as well as construction and application thereof. The 403th methionine of the O-type foot and mouth disease virus 3D protein is mutated into alanine, the recombinant virus strain rFMDV-M403A with the mutated O-type foot and mouth disease virus 3D protein is successfully constructed and saved by using a reverse genetic technology, and amino acid of the recombinant virus strain can be stably mutated in a passage process; the growth speed of the mutant strain is slower than that of a wild strain, and the virus titer is remarkably reduced; in an individual experiment, neonatal mouse infection shows that the mutant strain can improve the survival rate of neonatal mice, and the virus load and tissue lesion in the liver are remarkably reduced. The attenuated foot-and-mouth disease recombinant virus strain provided by the invention provides important significance for deep understanding of a foot-and-mouth disease virus pathogenic mechanism and a prevention and control strategy, and also provides an important theoretical basis for further development of a foot-and-mouth disease genetic engineering vaccine.

The invention relates to the technical field of public health information, in particular to an infectious disease transmission path generation and early warning method and system based on big data, and the method comprises the steps: collecting and cleaning multi-modal data, and obtaining a pulse event flow through neuromorphic coding; and constructing a variable order hyperedge graph in a second-level window, extracting loop life to adjust diffusion of the cellular automaton, and iteratively generating an infection prediction field. And then splicing the hyperedge graph, the prediction field and the topological fingerprint into a conditional tensor, and inputting the conditional tensor into a conditional score diffusion network to generate a future propagation event sequence. And constructing a tensor network according to the sequence, mapping the tensor network into Isin Hamiltonian, quickly selecting an intervention node through an optical delay ring reservoir and gradient descent, and issuing a ventilation or purification instruction. And after a virus load difference value before and after intervention is normalized, a tensor network, a diffusion network and a cellular automaton are synchronously updated to form a self-adaptive closed loop, so that a peak time error can be shortened, and the recall rate of a high-risk region is improved.

The invention belongs to the field of molecular biological detection, particularly relates to a quantitative composition, a kit, a method and application, and more particularly relates to an HBV quantitative composition, a kit, a method and application. The present invention provides a quantitative composition comprising a homologous vector of at least one portion of at least one of the C region, P region, X region, or S region of the HBV, and a quantitative vector, as well as primers and probes for amplifying the two vectors. The homologous vector is creatively introduced, and the concentration of nucleic acid to be detected is artificially increased, so that the stability and accuracy of PCR amplification reaction are improved. Particularly, in a sample with low virus load, the HBV can be well detected.

The invention discloses a porcine reproductive and respiratory syndrome virus mRNA (messenger Ribonucleic Acid) molecule and application thereof, and four mRNA vaccines GP35m-LNP, GP45m-LNP, GP345m-LNP and GP2345m-LNP are designed by combining structural protein GP2a, GP3, GP4 and GP5 genes of a PRRSV FJ1402 strain of NADC30-like. Mouse test results show that the GP345m-LNP can simultaneously induce strong humoral and cellular immune response, the GP2345m-LNP is secondary, and the effect is superior to that of an inactivated vaccine (only inducing humoral immunity). After immunization, the PRRSV FJ1402 strain is adopted for counteracting toxic substances, the virus load in blood and lungs of a GP345m-LNP group is obviously reduced, pathological injuries of the lungs are obviously relieved, the immune effect is superior to that of an inactivated vaccine group, and the vaccine has a relatively good application prospect.

The invention belongs to the field of molecular biological detection, particularly relates to a quantitative composition, a kit, a method and application, and more particularly relates to an HCV quantitative composition, a kit, a method and application. The present invention provides a quantitative composition comprising a homologous vector of at least one portion of at least one of at least one of the 5 'UTR region, CORE region, E1 region, E2 region, P7 region, NS2 region, NS3 region, NS4A region, NS4B region, NS5A region, NS5 region, or 3' UTR region of said HCV, and a quantitative vector, as well as primers and probes for amplifying both vectors. The homologous vector is creatively introduced, and the concentration of the sample to be detected is artificially increased, so that the stability and accuracy of PCR amplification reaction are improved. Particularly, in a sample with low virus load, the HCV can be well detected.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The present disclosure relates to a use of Genipin-1-β-D-gentiobioside in preparation of a drug, specifically for use in a drug that treats respiratory inflammatory injury caused by coronavirus, respiratory syncytial virus, or Mycoplasma pneumoniae infection. The present disclosure has discovered that Genipin-1-β-D-gentiobioside possesses the characteristics of reducing viral load, lung index, and inflammatory cytokines in lung tissue following coronavirus infection, respiratory syncytial virus infection, or Mycoplasma pneumoniae infection. It also demonstrates a significant protective effect against death caused by coronavirus infection.

A therapeutic light assembly used for reducing a patient's viral load including a housing containing at least one therapeutic light source configured to emit light at air exiting the patient's airway, a power source coupled to the at least therapeutic light source, and a tubing attachment coupled to the housing configured to secure the housing to a patient's tubing.

The invention discloses a fluorescent quantitative PCR (Polymerase Chain Reaction) primer probe and a kit for detecting abalone muscular dystrophy virus. The probe and the primer are designed for a highly conserved region of an AbSV genome, a real-time fluorescent PCR system is established, and the probe and the primer can be used for detection of abalone muscular dystrophy virus and quantitative analysis of virus load; the detection sensitivity is high, and 10 copies / mu L of viruses can be detected; the method is simple to operate, low in detection cost and wide in application range; the detection specificity is high, the detection speed is high, and the detection process can be completed in only 80 minutes.

The invention discloses a method, a system, equipment and a medium for detecting an HPV (human papilloma virus) DNA (deoxyribonucleic acid) integration event, and relates to the technical field of gene detection. According to the method, HPV types and virus loads (Ct values) pre-screened by qPCR are used as natural identifiers to guide grouping and mixing of samples, and HPV integrated event detection and sample tracing are synchronously realized through single sequencing. Clinical verification shows that compared with qPCR, the comprehensive sensitivity reaches 97.1%, and the cost is reduced by 60%. And a built-in targeted retest mechanism improves the reliability of a detection result. The invention provides a novel, traceable, economical and feasible solution, is used for high-throughput HPV-host genome integration feature analysis, balances cost, expandability and clinical accuracy, and provides a high-throughput and low-cost solution for HPV-related cancer screening.

The present inventors have conducted intensive studies on an antibody which controls HIV in an administration group with a high probability over a long period of time with one or several times of single-agent administration. As a result, the present inventors have surprisingly found that, when an SW-1C10 antibody, which is obtained by producing an antibody gene reported as 1C10 in silkworms, is singly administered only a few times, the viral load in the blood is suppressed to the detection limit or lower at an early stage in all of individuals to which the antibody has been administered, and moreover, the viral RNA load in the blood is maintained at the detection limit or lower for a long time of 12 weeks.

The utility model discloses an efficient low-resistance type fan pipe coil return air purification device which is provided with a purification shell, the upper side and the lower side of the purification shell are provided with a return air inlet and a return air outlet respectively, and a detachable nanofiber filter screen is installed in the purification shell. The front side wall of the purification shell is further provided with a pressure difference sensor, and a pressure tapping pipe opening high-pressure end and a pressure tapping pipe opening low-pressure end of the pressure difference sensor are connected to the return air inlet and the return air outlet respectively. An overhaul window is further formed in the front side wall of the purification shell, and an overhaul cover plate is mounted on the overhaul window; the purification device disclosed by the utility model has the main characteristics of high particulate matter purification efficiency and low wind resistance, and can be matched with a fan system to quickly improve the indoor air quality. Especially in crowded areas such as hospitals, air circulation is not good, the virus load in the air is high, and a safe breathing environment for patients, family members and medical staff can be created through positive air change of the breathing device.

The invention relates to the technical field of biological medicines, and particularly discloses application of a swine STING molecular agonist SR-717 in preparation of a pseudorabies virus infection resisting medicine. The swine STING molecular agonist SR-717 can be stably combined with swine STING protein, the promoter activity of a downstream signal molecule interferon regulatory factor 3 (IRF3) and I-type interferon (IFN beta) is enhanced, PRV replication can be remarkably inhibited, the virus load is reduced, and pathological changes of infected mouse lung, brain and other tissues are reduced. The SR-717 provided by the invention has good targeting property and immune activation ability, and is suitable for intervention treatment of porcine pseudorabies virus infection.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

This invention, entitled "A Method and Application for Target Gene Quantification in qPCR Using a Quantitative Internal Standard and a Comprehensive Correction Coefficient," belongs to the field of nucleic acid detection technology. The technical problem it addresses is that existing qPCR techniques require the establishment of a standard curve using a reference sample of known concentration, increasing reagent costs and experimental complexity, and resulting in poor reproducibility. The key technical solution is to provide a method for quantitative viral load qPCR analysis of a single sample. Specifically, it provides an internal standard with a known copy number, i.e., a quantitative internal standard, and establishes a correction method. Through a systematic error compensation mechanism, it achieves accurate quantification of the target gene. This method ensures both accuracy and reproducibility while simplifying detection design in clinical applications.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention discloses Lactobacillus crispatus and its use. The Lactobacillus crispatus is Lactobacillus crispatus chen-01 (Lactobacillus crispatus chen-01), and its deposit number is CGMCC NO.23396. Lactobacillus crispatus can be used to prepare medicines, and the medicines are used to treat and / or prevent HPV infection and vaginal infection. After the medicine prepared by the Lactobacillus crispatus is locally transplanted into the vagina of the present invention, the HPV viral load can be effectively reduced, the HPV clearance rate can be significantly improved, vaginitis can be effectively improved, and the diversity and abundance of vaginal flora can be significantly reduced; in addition, local vaginal transplantation of Lactobacillus crispatus can also significantly improve the vaginal microecological composition, which is close to that of normal healthy people.

The present invention relates to the field of biological control technology, and in particular to a thunbergii glycoside compound screened with PACT as a target and capable of exerting a broad-spectrum anti-respiratory virus effect and its application. The thunbergii glycoside II (TBM II) described in the present invention can reduce viral load and lung index, alleviate lung tissue lesions, reduce inflammatory cell infiltration and red blood cell exudation, thereby achieving the effect of improving respiratory viral infection. TBM II is a traditional Chinese medicine compound with PACT as a target and has a broad-spectrum anti-respiratory virus effect. It has been verified by experiments that it has a good anti-respiratory virus effect. It can be seen that the TBM II provided by the present invention provides a new therapeutic drug for respiratory viruses.

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.